These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7875638)

  • 1. Pharmacokinetic-pharmacodynamic modeling between pinacidil or pinacidil-N-oxide plasma levels and systemic and regional hemodynamic effects in healthy volunteers.
    Bellissant E; Chau NP; Thuillez C; Giudicelli JF
    Fundam Clin Pharmacol; 1994; 8(5):437-45. PubMed ID: 7875638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.
    Thuillez C; Pussard E; Bellissant E; Richer C; Kechrid R; Giudicelli JF
    Br J Clin Pharmacol; 1991 Jan; 31(1):33-9. PubMed ID: 2015168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.
    Bellissant E; Giudicelli JF
    Br J Clin Pharmacol; 1999 Dec; 48(6):801-10. PubMed ID: 10594483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.
    Girard P; Saumet JL; Dubois F; Boissel JP
    Eur J Clin Pharmacol; 1993; 44(2):177-82. PubMed ID: 8453963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and coronary hemodynamic effects of pinacidil in awake normotensive and hypertensive dogs.
    Kawashima S; Liang CS
    Hypertension; 1985; 7(4):525-32. PubMed ID: 3891613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment.
    Stone CK; Wellington KL; Willick A; Sullebarger JT; Liang CS
    J Clin Pharmacol; 1991 Apr; 31(4):333-41. PubMed ID: 2037705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of an antihypertensive vasodilator, pinacidil, on regional blood flow in conscious spontaneously hypertensive rats.
    Kimura S; Fujioka S; Fukui K; Tamaki T; Iwao H; Abe Y
    J Pharmacobiodyn; 1988 Jun; 11(6):430-7. PubMed ID: 3171884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of formulation on the pharmacokinetics of orally administered pinacidil in humans.
    McBurney A; Farrow PR; Ward JW
    J Pharm Sci; 1987 Dec; 76(12):940-1. PubMed ID: 3440941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pinacidil. Preclinical investigations.
    Ahnfelt-Rønne I
    Drugs; 1988; 36 Suppl 7():4-9. PubMed ID: 3076134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
    Ward JW; McBurney A; Farrow PR; Sharp P
    Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pinacidil on arterial and venous resistances and mean circulatory filling pressure in rats.
    Waite RP; Lim SL; Pang CC
    Br J Pharmacol; 1995 Oct; 116(4):2322-6. PubMed ID: 8564267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
    Carlsen JE; Kardel T; Hilden T; Tangø M; Trap-Jensen J
    Clin Physiol; 1981 Aug; 1(4):375-84. PubMed ID: 7199409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers.
    Bellissant E; Nguyen PC; Giudicelli JF
    J Cardiovasc Pharmacol; 1996 Sep; 28(3):470-8. PubMed ID: 8877596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic effects of a potassium channel activator (pinacidil) on repolarization parameters in healthy volunteers: a surface ECG study.
    Nony P; Girard P; Arnaud P; Rubel P; Fayn J; de Breyne B; Haugh MC; Girard I; Ferry S; Boissel JP
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):534-9. PubMed ID: 7505354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers.
    Bellissant E; Giudicelli JF
    Br J Clin Pharmacol; 1998 Oct; 46(4):383-93. PubMed ID: 9803988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of food on the bioavailability of sustained-release pinacidil in humans.
    McBurney A; Farrow PR; Ward JW
    J Pharm Sci; 1988 Jan; 77(1):68-9. PubMed ID: 3346824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive assessment of regional arteriolar and arterial dilating properties of lisinopril in healthy volunteers.
    Bellissant E; Thuillez C; Richer C; Pussard E; Giudicelli JF
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):500-8. PubMed ID: 7528307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
    Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
    Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.